ReviewInterface focus2019
Prostate-specific antigen glycoprofiling as diagnostic and prognostic biomarker of prostate cancer.
Review in Interface focus, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Comprehensive biochemical insights into derivatives of PSA and glycosylation-specific changes in PSA: role in diagnosis and management of prostate cancer.Clinical proteomics · 2026Review
- Applications of Plant Lectins in Detection and Targeted Therapy of Urological Cancers.Drug design, development and therapy · 2026Review
- Glycoproteomics of Gastrointestinal Cancers and Its Use in Clinical Diagnostics.Journal of proteome research · 2025Review
- Article
- MXene and prostate cancer: is there promising news?Nanomedicine (London, England) · 2025Review
- Association of Serum PSA, fPSA, and CEA Levels with Prognosis and Clinicopathological Characteristics in Prostate Cancer.Cancer management and research · 2025Article
- Integrating shear wave elastography and multiparametric MRI for accurate prostate cancer diagnosis.American journal of cancer research · 2025Article
- Portable Amperometric Biosensor Enhanced with Enzyme-Ternary Nanocomposites for Prostate Cancer Biomarker Detection.Biosensors · 2024Article
- N-Acetylated Monosaccharides and Derived Glycan Structures Occurring in N- and O-Glycans During Prostate Cancer Development.Cancers · 2024Review
- Assessment of Anti-Prostate Cancer Activity among Four Seaweeds, with Focus onFoods (Basel, Switzerland) · 2024Article
- Medical Relevance, State-of-the-Art and Perspectives of "Sweet Metacode" in Liquid Biopsy Approaches.Diagnostics (Basel, Switzerland) · 2024Review
- On-chip microscale isoelectric focusing enhances protein detection limit.Applied physics letters · 2024Article
- Glycoprofiling of proteins as prostate cancer biomarkers: A multinational population study.PloS one · 2024Article
- Clinical analysis of EV-Fingerprint to predict grade group 3 and above prostate cancer and avoid prostate biopsy.Cancer medicine · 2023Article
- Amperometric Miniaturised Portable Enzymatic Nanobiosensor for the Ultrasensitive Analysis of a Prostate Cancer Biomarker.Journal of functional biomaterials · 2023Article
- Discrimination between protein glycoforms using lectin-functionalised gold nanoparticles as signal enhancers.Nanoscale horizons · 2023Article
- Capitalizing glycomic changes for improved biomarker-based cancer diagnostics.Exploration of targeted anti-tumor therapy · 2023Review
- Correlations between serum levels of microRNA-148a-3p and microRNA-485-5p and the progression and recurrence of prostate cancer.BMC urology · 2022Article
- Glycoforms of human prostate-specific membrane antigen (PSMA) in human cells and prostate tissue.The Prostate · 2022Article
- Gold Nanoparticles Based Optical Biosensors for Cancer Biomarker Proteins: A Review of the Current Practices.Frontiers in bioengineering and biotechnology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The initial part of this review details the controversy behind the use of a serological level of prostate-specific antigen (PSA) for the diagnostics of prostate cancer (PCa). Novel biomarkers are in demand for PCa diagnostics, outperforming traditional PSA tests. The review provides a detailed and comprehensive summary that PSA glycoprofiling can effectively solve this problem, thereby considerably reducing the number of unnecessary biopsies. In addition, PSA glycoprofiling can serve as a prognostic PCa biomarker to identify PCa patients with an aggressive form of PCa, avoiding unnecessary further treatments which are significantly life altering (incontinence or impotence).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.